Pfizer Inc
—- Market cap
- —
- Debt
- +$64.80B
- Cash
- −$1.14B
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: PFE stock price vs CSCO: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at CSCO's multiple
Needs CSCO P/E.
Implied fair value · at PFE's multiple
Needs PFE P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Nine period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
PFIZER INC · implied price per share
Bear
$10.17
Base
$12.82
Bull
$17.53
CISCO SYSTEMS, INC. · implied price per share
Bear
$32.30
Base
$38.62
Bull
$46.85
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
JOHNSON & JOHNSON
PFE vs JNJ
Merck & Co., Inc.
PFE vs MRK
AbbVie Inc.
PFE vs ABBV
BRISTOL MYERS SQUIBB CO
PFE vs BMY
ELI LILLY & Co
PFE vs LLY
AMGEN INC
PFE vs AMGN
CIENA CORP
PFE vs CIEN
Palo Alto Networks Inc
PFE vs PANW
JUNIPER NETWORKS INC
PFE vs JNPR
Fortinet, Inc.
PFE vs FTNT
Arista Networks, Inc.
PFE vs ANET
Leidos Holdings, Inc.
PFE vs LDOS
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe PFE can re-accelerate revenue growth and sustain its high gross margin while improving net margin and leverage, then the current discount could be attractive; otherwise, the stock looks closer to fairly valued given its weak growth, middling quality score, and leverage versus CSCO.
PFE’s current price of $24.32 is far below CSCO-implied price of $60.10, implying 147.1% upside on a P/E basis. However, that CSCO multiple appears difficult to justify given PFE’s weaker growth and profitability profile versus CSCO.
Supporting Metrics